<HTML>
<HEAD>
<TITLE>sv8</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="center" style="font-size: 10pt"><B>As filed with the
Securities and Exchange Commission on July&nbsp;30, 2004</B>



<div align="right" style="font-size: 10pt"><B>Registration No.&nbsp;333-</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div>



<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">







<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>


<P align="center" style="font-size: 10pt"><HR align="center" size="1" noshade width="25%">


<P align="center" style="font-size: 18pt"><B>FORM S-8</B>

<DIV align="center" style="font-size: 10pt">REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF 1933</DIV>



<P align="center" style="font-size: 10pt"><HR align="center" size="1" noshade width="25%">


<P align="center" style="font-size: 24pt"><B>MannKind Corporation</B>


<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B><BR>
(State or other jurisdiction<BR>
of incorporation or organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>13-3607736</B><BR>
(I.R.S. Employer Identification No.)</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><B>28903 North Avenue Paine<BR>
Valencia, CA 91355<BR>
(661)&nbsp;775-5300</B>


<DIV align="center" style="font-size: 10pt">(Address of Principal Executive Offices)</DIV>



<P align="center" style="font-size: 10pt"><HR align="center" size="1" noshade width="25%">



<P align="center" style="font-size: 10pt"><B>Pharmaceutical Discovery Corporation 1991 Stock Option Plan<BR>
Pharmaceutical Discovery Corporation 1999 Stock Plan<BR>
AlleCure Corp. 2000 Stock Option and Stock Plan<BR>
CTL ImmunoTherapies Corp. 2000 Stock Option and Stock Plan<BR>
2004 Employee Stock Purchase Plan<BR>
2004 Equity Incentive Plan<BR>
2004 Non-Employee Directors&#146; Stock Option Plan</B>


<DIV align="center" style="font-size: 10pt">(Full title of the plans)</DIV>



<P align="center" style="font-size: 10pt"><HR align="center" size="1" noshade width="25%">



<P align="center" style="font-size: 10pt"><B>Alfred E. Mann<BR>
Chief Executive Officer and Chairman<BR>
MannKind Corporation<BR>
28903 North Avenue Paine<BR>
Valencia, CA 91355</B>


<DIV align="center" style="font-size: 10pt">(Name and address of agent for service)</DIV>



<P align="center" style="font-size: 10pt"><B>(661)&nbsp;775-5300</B>


<DIV align="center" style="font-size: 10pt">(Telephone number, including area code, of agent for service)</DIV>



<P align="center" style="font-size: 10pt"><HR align="center" size="1" noshade width="25%">



<P align="center" style="font-size: 10pt"><B>Copies to:<BR>
Frederick T. Muto, Esq.<BR>
Jeremy D. Glaser, Esq.<BR>
COOLEY GODWARD LLP<BR>
4401 Eastgate Mall<BR>
San Diego, CA 92121-9109<BR>
(858)&nbsp;550-6000</B>



<P align="center" style="font-size: 10pt"><HR align="center" size="1" noshade width="25%">




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt"><B>CALCULATION OF REGISTRATION FEE</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="26%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="18%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="16%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
</TR>


<TR style="font-size: 1px" valign="bottom">
    <TD colspan="9"><HR size="4" noshade>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Proposed maximum</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Proposed maximum</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>&nbsp;</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center"><B>Title of securities</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Amount to be</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>offering price per</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>aggregate offering</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Amount of</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center"><B>to be registered</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>registered (1)</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>share</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>price</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>registration fee</B></TD>
</TR>
<TR style="font-size: 1px" valign="bottom">
    <TD colspan="9"><HR size="1" noshade>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD align="center"><DIV style="margin-left:0px; text-indent:-0px">Common Stock, par value $.01 per
share, issuable
under the
Pharmaceutical
Discovery
Corporation 1991
Stock Option Plan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">126,099 shares (2)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$6.11(3)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$770,465(3)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$98</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">

<TD align="center"><DIV style="margin-left:0px; text-indent:-0px">Common Stock, par value $.01 per
share, issuable
under the
Pharmaceutical
Discovery
Corporation 1999
Stock Plan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">305,430 shares (4)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$7.95(5)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$2,428,169(5)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$308</TD>
</TR>


<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">

<TD align="center"><DIV style="margin-left:0px; text-indent:-0px">Common Stock, par value $.01 per
share, issuable
under the AlleCure
Corp. 2000 Stock
Option and Stock
Plan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">14,366 shares (6)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$22.59(7)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$324,528(7)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$41</TD>
</TR>


<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">

<TD align="center"><DIV style="margin-left:0px; text-indent:-0px">Common Stock, par value $.01 per
share, issuable
under the CTL
ImmunoTherapies
Corp. 2000 Stock
Option and Stock
Plan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">105,981 shares (8)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$13.03(9)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$1,380,932(9)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$175</TD>
</TR>


<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">

<TD align="center"><DIV style="margin-left:0px; text-indent:-0px">Common Stock, par value $.01 per
share, issuable
under the 2004
Employee Stock
Purchase Plan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2,000,000 shares (10)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$14.00(11)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$28,000,000(11)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$3,548</TD>
</TR>


<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">

<TD align="center"><DIV style="margin-left:0px; text-indent:-0px">Common Stock, par value $.01 per
share, issuable
under the 2004
Equity Incentive
Plan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">5,000,000 shares (12)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$8.64-$14.00 (13)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$62,847,691(13)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$7,963</TD>
</TR>


<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">

<TD align="center"><DIV style="margin-left:0px; text-indent:-0px">Common Stock, par value $.01 per
share, issuable
under the 2004
Non-Employee
Directors&#146; Stock
Option Plan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">800,000 shares (14)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$14.00(11)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$11,200,000(11)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$1,419</TD>
</TR>


<TR style="font-size: 1px" valign="bottom">
    <TD colspan="9"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD align="center"><DIV style="margin-left:0px; text-indent:-0px">Common Stock, par value $.01 per
shares, issuable
pursuant to options
granted outside of
the Registrant&#146;s
plans</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">240,972 shares (15)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$25.23(16)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$6,079,724(16)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$770</TD>
</TR>

<TR style="font-size: 1px" valign="bottom">
    <TD colspan="9"><HR size="1" noshade>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:10px; text-indent:-0px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">8,592,848 shares</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">N/A</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$113,031,509</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$14,322</TD>
</TR>
<TR style="font-size: 1px" valign="bottom">
    <TD colspan="9"><HR size="4" noshade>&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" nowrap align="right">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;), this Registration Statement also registers any
additional shares of Registrant&#146;s Common Stock, par value $0.01 per share
(the &#147;Common Stock&#148;), that become issuable under any of the plans by
reason of any stock dividend, stock split, recapitalization or other
similar transaction effected without receipt of consideration that
increases the number of outstanding shares of Common Stock.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" nowrap align="right">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Comprised solely of shares of Common Stock reserved for issuance upon the
exercise of options outstanding under the Pharmaceutical Discovery
Corporation 1991 Stock Option Plan (the &#147;1991 Plan&#148;). No additional
options may be granted under the 1991 Plan.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" nowrap align="right">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Estimated solely for the purposes of calculating the registration fee
pursuant to Rule 457(h) of the Securities Act. The Proposed maximum
offering price per share and Proposed maximum aggregate offering price for
the 126,099 shares reserved for issuance under the 1991 Plan are
calculated using a weighted average exercise price for such shares of
$6.11.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" nowrap align="right">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Comprised solely of shares of Common Stock reserved for issuance upon the
exercise of options outstanding under the Pharmaceutical Discovery
Corporation 1999 Stock Plan (the &#147;1999 Plan&#148;). No additional options may
be granted under the 1999 Plan.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" nowrap align="right">(5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Estimated solely for the purposes of calculating the registration fee
pursuant to Rule 457(h) of the Securities Act. The Proposed maximum
offering price per share and Proposed maximum aggregate offering price for
the 305,430 shares reserved for issuance under the 1999 Plan are
calculated using a weighted average exercise price for such shares of
$7.95.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" nowrap align="right">(6)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Comprised solely of shares of Common Stock reserved for issuance upon the
exercise of options outstanding under the AlleCure Corp. 2000 Stock Option
and Stock Plan (the &#147;AlleCure Plan&#148;). No additional options may be
granted under the AlleCure Plan.</TD>
</TR>

</TABLE>
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" nowrap align="right">(7)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Estimated solely for the purposes of calculating the registration fee
pursuant to Rule 457(h) of the Securities Act. The Proposed maximum
offering price per share and Proposed maximum aggregate offering price for
the 14,366 shares reserved for issuance under the AlleCure Plan are
calculated using a weighted average exercise price for such shares of
$22.59.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" nowrap align="right">(8)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Comprised solely of shares of Common Stock reserved for issuance upon the
exercise of options outstanding under the CTL ImmunoTherapies Corp. 2000
Stock Option and Stock Plan (the &#147;CTL Plan&#148;). No additional
options may be granted under the CTL&nbsp;Plan.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" nowrap align="right">(9)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Estimated solely for the purposes of calculating the registration fee
pursuant to Rule 457(h) of the Securities Act. The Proposed maximum
offering price per share and Proposed maximum aggregate offering price for
the 105,981 shares reserved for issuance under the CTL Plan are calculated
using a weighted average exercise price for such shares of $13.03.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" nowrap align="right">(10)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Represents 2,000,000 shares of Common Stock initially available for
future grants under the Registrant&#146;s 2004 Employee Stock Purchase Plan
(the &#147;ESPP&#148;). The ESPP provides that an additional number of shares will
automatically be added annually to the shares authorized for issuance
under the ESPP on the first day of each calendar year, from 2005 until
2014. The number of shares added each year will be equal to the lesser
of: one percent of the total number of shares of Common Stock outstanding
on January 1 of the current fiscal year; 700,000 shares of Common Stock;
or a number of shares of Common Stock that may be determined each year by
the board of directors of MannKind Corporation (the &#147;Registrant&#148;).</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" nowrap align="right">(11)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This estimate is made pursuant to Rule 457(h) of the Securities Act
solely for purposes of calculating the registration fee, and is based on
the price per share in the initial public offering (the &#147;Offering&#148;) of the
Common Stock as set forth in the Registrant&#146;s prospectus filed with the
Securities and Exchange Commission (the &#147;Commission&#148;) on July&nbsp;27, 2004
pursuant to Rule 424(b) under the Securities Act.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" nowrap align="right">(12)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Represents 1,334,386 shares of Common Stock reserved for issuance upon
exercise of options outstanding under the Registrant&#146;s 2004 Equity
Incentive Plan (the &#147;2004 Plan&#148;) and 3,665,614 shares of Common Stock
available for future grants under the 2004 Plan.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" nowrap align="right">(13)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Estimated solely for purposes of calculating the registration fee
pursuant to Rule 457(h) of the Securities Act. The Proposed maximum
offering price per share and Proposed maximum aggregate offering price for
the 1,334,386 shares of Common Stock reserved for issuance upon the
exercise of options outstanding under the 2004 Plan are calculated using a
weighted average exercise price for such shares of $8.64 per share. The
Proposed maximum offering price per share and Proposed maximum aggregate
offering price for the 3,665,614 shares of Common Stock available for
future grants under the 2004 Plan are calculated using the price per share
in the Offering.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" nowrap align="right">(14)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Represents 800,000 shares of Common Stock initially available for future
grants under the Registrant&#146;s 2004 Non-Employee Directors&#146; Stock Option
Plan.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" nowrap align="right">(15)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Comprised solely of shares of Common Stock reserved for issuance upon
exercise of outstanding options granted outside of the Registrant&#146;s plans.</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" nowrap align="right">(16)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Estimated solely for the purposes of calculating the registration fee
pursuant to Rule 457(h) of the Securities Act. The Proposed maximum
offering price per share and Proposed maximum aggregate offering price for
the 240,972 shares reserved for issuance pursuant to outstanding options
granted outside of the Registrant&#146;s plans are calculated using a weighted
average exercise price for such shares of $25.23.</TD>
</TR>

</TABLE>


<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">PART I</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">ITEM 1. PLAN INFORMATION.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#002">ITEM 2. REGISTRANT INFORMATION AND EMPLOYEE PLAN ANNUAL INFORMATION.</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">PART II</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#004">ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#005">ITEM 4. DESCRIPTION OF SECURITIES.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#006">ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#007">ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#008">ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#009">ITEM 8. EXHIBITS.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#010">ITEM 9. UNDERTAKINGS.</A></TD></TR>
<TR><TD colspan="9"><A HREF="#011">SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="#012">EXHIBIT INDEX</A></TD></TR>
<TR><TD colspan="9"><A HREF="v00627exv5w1.txt">Opinion of Cooley Godward LLP</A></TD></TR>
<TR><TD colspan="9"><A HREF="v00627exv23w1.txt">Consent of Deloitte & Touche LLP</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>






<!-- link1 "PART I" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="center" style="font-size: 10pt"><B>PART I</B>



<P align="center" style="font-size: 10pt"><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B>


<!-- link2 "ITEM 1. PLAN INFORMATION." -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="left" style="font-size: 10pt"><B>ITEM 1. PLAN INFORMATION.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not required to be filed with this Registration Statement.

<!-- link2 "ITEM 2. REGISTRANT INFORMATION AND EMPLOYEE PLAN ANNUAL INFORMATION." -->
<DIV align="left"><A NAME="002"></A></DIV>

<P align="left" style="font-size: 10pt"><B>ITEM 2. REGISTRANT INFORMATION AND EMPLOYEE PLAN ANNUAL INFORMATION.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not required to be filed with this Registration Statement.


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "PART II" -->
<DIV align="left"><A NAME="003"></A></DIV>

<P align="center" style="font-size: 10pt"><B>PART II</B>



<P align="center" style="font-size: 10pt"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B>


<!-- link2 "ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE." -->
<DIV align="left"><A NAME="004"></A></DIV>

<P align="left" style="font-size: 10pt"><B>ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Registrant hereby incorporates by reference into this Registration
Statement the following documents previously filed by the Registrant with the
Commission:


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Registrant&#146;s prospectus filed on July&nbsp;28, 2004 pursuant to Rule
424(b) under the Securities Act, relating to the registration statement on Form
S-1 (File No.&nbsp;333-115020), which contains audited financial statements for the
Registrant&#146;s latest fiscal year for which such statements have been filed.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The description of the Common Stock contained in the Registrant&#146;s
registration statement on Form 8-A filed on July&nbsp;23, 2004 (File No.&nbsp;000-50865),
under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;),
including any amendment or report filed for the purpose of updating such
description.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All documents, reports and definitive proxy or information statements
filed pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act after
the date of this Registration Statement and prior to the filing of a
post-effective amendment which indicates that all securities offered hereby
have been sold or which deregisters all securities then remaining unsold shall
be deemed to be incorporated by reference into this Registration Statement and
to be a part hereof from the date of filing of such documents. Any statement
contained in a document incorporated or deemed to be incorporated herein by
reference shall be deemed to be modified or superseded for purposes of this
Registration Statement to the extent that a statement herein or in any other
subsequently filed document which also is or is deemed to be incorporated by
reference herein modifies or supersedes that statement. Any such statement so
modified or superseded shall not constitute a part of this Registration
Statement, except as so modified or superseded.

<!-- link2 "ITEM 4. DESCRIPTION OF SECURITIES." -->
<DIV align="left"><A NAME="005"></A></DIV>

<P align="left" style="font-size: 10pt"><B>ITEM 4. DESCRIPTION OF SECURITIES.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

<!-- link2 "ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL." -->
<DIV align="left"><A NAME="006"></A></DIV>

<P align="left" style="font-size: 10pt"><B>ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The validity of the issuance of the common stock offered by this
prospectus and certain other legal matters are being passed on for us by our
counsel, Cooley Godward LLP, San Diego, California.

<!-- link2 "ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS." -->
<DIV align="left"><A NAME="007"></A></DIV>

<P align="left" style="font-size: 10pt"><B>ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Registrant is incorporated under the laws of the State of Delaware.
Section&nbsp;145 of the Delaware General Corporation Law provides that a Delaware
corporation may indemnify any persons who are, or are threatened to be made,
parties to any threatened, pending or completed action, suit or proceeding,
whether civil, criminal, administrative or investigative (other than an action
by or in the right of such corporation), by reason of the fact that such person
is or was an officer, director, employee or agent of such corporation, or is or
was serving at the request of such corporation as an officer, director,
employee or agent of another corporation or enterprise. The indemnity may
include expenses (including attorneys&#146; fees), judgments, fines and amounts paid
in settlement actually and reasonably incurred by such person in connection
with such action, suit or proceeding, provided that such person acted in good
faith and in a manner he or she reasonably believed to be in or not opposed to
the corporation&#146;s best interests and, with respect to any criminal action or
proceeding, had no reasonable cause to believe that his or her conduct was
illegal. A Delaware corporation may indemnify any persons who are, or are
threatened to be made, a party to any threatened, pending or completed action
or suit by or in the right of the corporation by reason of the fact that such
person is or was a director, officer, employee or agent of such corporation, or
is or was serving at the request of such corporation as a director, officer,
employee or agent of another corporation or enterprise. The indemnity may
include expenses (including attorneys&#146; fees) actually and reasonably incurred
by such person in connection with the defense or settlement of such action or
suit provided such person acted in good faith and in a manner he or she
reasonably believed to be in or not opposed to the corporation&#146;s best interests
except that no


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<P align="left" style="font-size: 10pt">indemnification is permitted without judicial approval if the officer or
director is adjudged to be liable to the corporation. Where an officer or
director is successful on the merits or otherwise in the defense of any action
referred to above, the corporation must indemnify him or her against the
expenses which such officer or director has actually and reasonably incurred.
The Registrant&#146;s amended and restated certificate of incorporation and amended
and restated bylaws, which will become effective upon the completion of the
Offering, provide for the indemnification of the Registrant&#146;s directors and
officers to the fullest extent permitted under the Delaware General Corporation
Law.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;102 of the Delaware General Corporation Law permits a corporation
to provide in its certificate of incorporation that a director of the
corporation shall not be personally liable to the corporation or its
stockholders for monetary damages for breach of fiduciary duties as a director,
except for liability:


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>for any transaction from which the director derives an
improper personal benefit;</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>for acts or omissions not in good faith or that involve
intentional misconduct or a knowing violation of law;</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>for acts related to unlawful stock repurchases, redemptions
or other distributions or payment of dividends; or</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>for any breach of a director&#146;s duty of loyalty to the
corporation or its stockholders.</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Registrant&#146;s amended and restated certificate of incorporation and
amended and restated bylaws include such a provision. Expenses incurred by any
officer or director in defending any such action, suit or proceeding in advance
of its final disposition shall be paid by the Registrant upon delivery to the
Registrant of an undertaking, by or on behalf of such director or officer, to
repay all amounts so advanced if it shall ultimately be determined that such
director or officer is not entitled to be indemnified by the Registrant.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;174 of the Delaware General Corporation Law provides, among other
things, that a director, who willfully or negligently approves of an unlawful
payment of dividends or an unlawful stock purchase or redemption, may be held
liable for such actions. A director who was either absent when the unlawful
actions were approved, or dissented at the time, may avoid liability by causing
his or her dissent to such actions to be entered in the books containing
minutes of the meetings of the board of directors at the time such action
occurred or immediately after such absent director receives notice of the
unlawful acts.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As permitted by the Delaware General Corporation Law, the Registrant has
entered into indemnity agreements with each of our directors and executive
officers, that require the Registrant to indemnify such persons against any and
all expenses (including attorneys&#146; fees), witness fees, damages, judgments,
settlements and other amounts incurred (including expenses of a derivative
action) in connection with any action, suit or proceeding, whether actual or
threatened, to which any such person may be made a party by reason of the fact
that such person is or was a director, an officer or an employee of the
Registrant or any of its affiliated enterprises, provided that such person
acted in good faith and in a manner such person reasonably believed to be in or
not opposed to the Registrant&#146;s best interests and, with respect to any
criminal proceeding, had no reasonable cause to believe his or her conduct was
unlawful. The indemnification agreements also set forth certain procedures
that will apply in the event of a claim for indemnification thereunder.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At present, there is no pending litigation or proceeding involving any of
the Registrant&#146;s directors or executive officers as to which indemnification is
required or permitted, and the Registrant is not aware of any threatened
litigation or proceeding that may result in a claim for indemnification. The
Registrant has an insurance policy covering its officers and directors with
respect to certain liabilities, including liabilities arising under the
Securities Act or otherwise.

<!-- link2 "ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED." -->
<DIV align="left"><A NAME="008"></A></DIV>

<P align="left" style="font-size: 10pt"><B>ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link2 "ITEM 8. EXHIBITS." -->
<DIV align="left"><A NAME="009"></A></DIV>

<P align="left" style="font-size: 10pt"><B>ITEM 8. EXHIBITS.</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="89%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>&nbsp;</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid gray"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid gray"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">3.1(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Registrant&#146;s Amended and Restated Certificate of Incorporation, to be effective upon
completion of the Offering.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">3.2(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Registrant&#146;s Amended and Restated Bylaws, to be effective upon completion of the
Offering.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.1(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Common Stock Certificate.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.2(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Registration Rights Agreement made and entered into as of October&nbsp;15, 1998 by and among CTL
ImmunoTherapies Corp., Medical Research Group, LLC, McLean Watson Advisory Inc. and Alfred E.
Mann, as amended.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">5.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Opinion of Cooley Godward LLP.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">23.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of Deloitte &#038; Touche
LLP, Independent Registered Public Accounting Firm.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">23.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of Cooley Godward LLP. Reference is made to Exhibit&nbsp;5.1.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">24.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Power of Attorney. Reference is made to the signature page hereto.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pharmaceutical Discovery Corporation 1991 Stock Option Plan.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.2(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pharmaceutical Discovery Corporation 1999 Stock Plan and Form of Stock Option Plan thereunder.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.3(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">AlleCure Corp. 2000 Stock Option and Stock Plan.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.4(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CTL ImmunoTherapies Corp. 2000 Stock Option and Stock Plan.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.5(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2004 Employee Stock Purchase Plan and Form of Offering Document thereunder.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.6(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2004 Equity Incentive Plan and Form of Stock Option Agreement thereunder.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.7(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2004 Non-Employee Directors&#146; Stock Option Plan and Form of Stock Option Agreement thereunder.</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>




<P>
<HR size="1" width="18%" align="left" noshade>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top">
    <TD width="1%" nowrap align="right">(1)</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="96%">Filed as an exhibit to the Registrant&#146;s Registration Statement on Form
S-1, as amended (File No.&nbsp;333-115020), originally filed with the
Commission on April&nbsp;30, 2004, and incorporated herein by reference.</TD>
</TR>

</TABLE>


<!-- link2 "ITEM 9. UNDERTAKINGS." -->
<DIV align="left"><A NAME="010"></A></DIV>

<P align="left" style="font-size: 10pt"><B>ITEM 9. UNDERTAKINGS.</B>


<P align="left" style="font-size: 10pt">A. The undersigned Registrant hereby undertakes: (1)&nbsp;to file, during any
period in which offers or sales are being made, a post-effective amendment to
this Registration Statement: (i)&nbsp;to include any prospectus required by section
10(a)(3) of the Securities Act; (ii)&nbsp;to reflect in the prospectus any facts or
events arising after the effective date of the registration statement (or the
most recent post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set forth in the
registration statement; and (iii)&nbsp;to include any material information with
respect to the plan of distribution not previously disclosed in the
registration statement or any material change to such information in the
registration statement; (2)&nbsp;that, for the purpose of determining any liability
under the Securities Act, each such post-effective amendment shall be deemed to
be a new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof; and (3)&nbsp;to remove from registration by means of a
post-effective amendment any of the securities being registered which remain
unsold at the termination of the offering.



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<P align="left" style="font-size: 10pt">B. The undersigned Registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act, each filing of the
Registrant&#146;s annual report pursuant to Section 13(a) or 15(d) of the Exchange
Act that is incorporated by reference in this Registration Statement shall be
deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.


<P align="left" style="font-size: 10pt">C. Insofar as indemnification for liabilities arising under the Securities Act
may be permitted to directors, officers and controlling persons of the
Registrant pursuant to the indemnification provisions summarized in Item&nbsp;6 or
otherwise, the Registrant has been advised that in the opinion of the
Commission such indemnification is against public policy as expressed in the
Securities Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the
Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the Registrant will, unless in
the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue.



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="011"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>


<P align="left" style="font-size: 10pt">Pursuant to the requirements of the Securities Act of 1933, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-8 and has duly caused this Registration
Statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Valencia, State of California, on
July&nbsp;30, 2004.



<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top">&nbsp;</TD>
    <TD colspan="3"><B>MANNKIND CORPORATION</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000">/s/ ALFRED E. MANN</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">Alfred E. Mann&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">Chief Executive Officer and
Chairman&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt"><B>POWER OF ATTORNEY</B>




<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>KNOW ALL PERSONS BY THESE PRESENTS</B>, that each person whose signature
appears below constitutes and appoints Hakan S. Edstrom, Richard L. Anderson
and David Thomson, and each or any one of them, his or her true and lawful
attorney-in-fact and agent, with full power of substitution and resubstitution,
for him or her and in his or her name, place and stead, in any and all
capacities, to sign any and all amendments (including post-effective
amendments) to this Registration Statement, and to file the same, with all
exhibits thereto, and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorneys-in-fact and
agents, and each of them, full power and authority to do and perform each and
every act and thing requisite and necessary to be done in connection therewith,
as fully to all intents and purposes as he or she might or could do in person,
hereby ratifying and confirming all that said attorneys-in-fact and agents, or
any of them, or their or his substitutes or substitute, may lawfully do or
cause to be done by virtue hereof.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement has been signed by the following persons in the
capacities and on the dates indicated.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="32%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center"><B>Signature</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Title</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Date</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">

<TD valign="top" align="center"><DIV style="margin-left:0px; text-indent:-0px">/s/
ALFRED E. MANN<HR size="1" noshade>
Alfred E. Mann
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Executive Officer and
Chairman of the Board of
Directors (<I>Principal Executive
Officer</I>)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">July&nbsp;30, 2004</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">

<TD valign="top" align="center"><DIV style="margin-left:0px; text-indent:-0px">/s/
HAKAN S. EDSTROM<HR size="1" noshade>
Hakan S. Edstrom
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President, Chief Operating
Officer and Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">July&nbsp;30, 2004</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">

<TD valign="top" align="center"><DIV style="margin-left:0px; text-indent:-0px">/s/
RICHARD L. ANDERSON<HR size="1" noshade>
Richard L. Anderson
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Corporate Vice President and
Chief Financial Officer
(<I>Principal Financial and
Accounting Officer</I>)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">July&nbsp;30, 2004</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">

<TD valign="top" align="center"><DIV style="margin-left:0px; text-indent:-0px">/s/
KATHLEEN CONNELL, Ph.D.<HR size="1" noshade>
Kathleen Connell, Ph.D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">July&nbsp;22, 2004</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">

<TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ RONALD CONSIGLIO<HR size="1" noshade>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">July&nbsp;30, 2004</TD>
</TR>

<TR valign="bottom">
    <TD valign="top" align="center"><DIV style="margin-left:0px; text-indent:-0px">Ronald Consiglio</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="32%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center"><B>Signature</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Title</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Date</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">

<TD valign="top" align="center"><DIV style="margin-left:0px; text-indent:-0px">/s/
LLEW KELTNER, M.D., Ph.D.<HR size="1" noshade>
Llew Keltner, M.D., Ph.D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">July&nbsp;28, 2004</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">

<TD valign="top" align="center"><DIV style="margin-left:0px; text-indent:-0px">/s/
MICHAEL FRIEDMAN, M.D.<HR size="1" noshade>
Michael Friedman, M.D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">July&nbsp;20, 2004</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">

<TD valign="top" align="center"><DIV style="margin-left:0px; text-indent:-0px">/s/
KENT KRESA<HR size="1" noshade>
Kent Kresa
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">July&nbsp;30, 2004</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">

<TD valign="top" align="center"><DIV style="margin-left:0px; text-indent:-0px">/s/
DAVID MACCALLUM<HR size="1" noshade>
David MacCallum
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">July&nbsp;22, 2004</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- link1 "EXHIBIT INDEX" -->
<DIV align="left"><A NAME="012"></A></DIV>

<P align="center" style="font-size: 10pt"><B>EXHIBIT INDEX</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="89%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>&nbsp;</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid gray"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid gray"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">3.1(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Registrant&#146;s Amended and Restated Certificate of Incorporation, to be effective upon
completion of the Offering.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">3.2(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Registrant&#146;s Amended and Restated Bylaws, to be effective upon completion of the
Offering.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.1(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Common Stock Certificate.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.2(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Registration Rights Agreement made and entered into as of October&nbsp;15, 1998 by and among CTL
ImmunoTherapies Corp., Medical Research Group, LLC, McLean Watson Advisory Inc. and Alfred E.
Mann, as amended.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">5.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Opinion of Cooley Godward LLP.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">23.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of Deloitte &#038; Touche
LLP, Independent Registered Public Accounting Firm.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">23.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of Cooley Godward LLP. Reference is made to Exhibit&nbsp;5.1.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">24.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Power of Attorney. Reference is made to the signature page hereto.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pharmaceutical Discovery Corporation 1991 Stock Option Plan.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.2(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pharmaceutical Discovery Corporation 1999 Stock Plan and Form of Stock Option Plan thereunder.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.3(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">AlleCure Corp. 2000 Stock Option and Stock Plan.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.4(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CTL ImmunoTherapies Corp. 2000 Stock Option and Stock Plan.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.5(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2004 Employee Stock Purchase Plan and Form of Offering Document thereunder.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.6(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2004 Equity Incentive Plan and Form of Stock Option Agreement thereunder.</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.7(1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2004 Non-Employee Directors&#146; Stock Option Plan and Form of Stock Option Agreement thereunder.</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>




<P>
<HR size="1" width="18%" align="left" noshade>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top">
    <TD width="1%" nowrap align="right">(1)</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="96%">Filed as an exhibit to the Registrant&#146;s Registration Statement on Form
S-1, as amended (File No.&nbsp;333-115020), originally filed with the
Commission on April&nbsp;30, 2004, and incorporated herein by reference.</TD>
</TR>

</TABLE>




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>
[{"type": "S-8", "sequence": "1", "filename": "v00627sv8.htm", "description": "MANNKIND CORPORATION", "secsgml_size_bytes": 60305}]
{"company-data": {"conformed-name": "MANNKIND CORP", "cik": "0000899460", "assigned-sic": "2834"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-117811", "film-number": "04942681"}, "business-address": {"street1": "28903 NORTH AVE PAINE", "city": "VALENCIA", "state": "CA", "zip": "91355", "phone": "6617755300"}}
sv8
Table of Contents
As filed with the
Securities and Exchange Commission on July 30, 2004
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
MannKind Corporation
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation or organization)
13-3607736
(I.R.S. Employer Identification No.)
28903 North Avenue Paine
Valencia, CA 91355
(661) 775-5300
(Address of Principal Executive Offices)
Pharmaceutical Discovery Corporation 1991 Stock Option Plan
Pharmaceutical Discovery Corporation 1999 Stock Plan
AlleCure Corp. 2000 Stock Option and Stock Plan
CTL ImmunoTherapies Corp. 2000 Stock Option and Stock Plan
2004 Employee Stock Purchase Plan
2004 Equity Incentive Plan
2004 Non-Employee Directors' Stock Option Plan
(Full title of the plans)
Alfred E. Mann
Chief Executive Officer and Chairman
MannKind Corporation
28903 North Avenue Paine
Valencia, CA 91355
(Name and address of agent for service)
(661) 775-5300
(Telephone number, including area code, of agent for service)
Copies to:
Frederick T. Muto, Esq.
Jeremy D. Glaser, Esq.
COOLEY GODWARD LLP
4401 Eastgate Mall
San Diego, CA 92121-9109
(858) 550-6000
Table of Contents
CALCULATION OF REGISTRATION FEE
Proposed maximum
Proposed maximum
Title of securities
Amount to be
offering price per
aggregate offering
Amount of
to be registered
registered (1)
share
price
registration fee
Common Stock, par value $.01 per
share, issuable
under the
Pharmaceutical
Discovery
Corporation 1991
Stock Option Plan
126,099 shares (2)
$6.11(3)
$770,465(3)
$98
Common Stock, par value $.01 per
share, issuable
under the
Pharmaceutical
Discovery
Corporation 1999
Stock Plan
305,430 shares (4)
$7.95(5)
$2,428,169(5)
$308
Common Stock, par value $.01 per
share, issuable
under the AlleCure
Corp. 2000 Stock
Option and Stock
Plan
14,366 shares (6)
$22.59(7)
$324,528(7)
$41
Common Stock, par value $.01 per
share, issuable
under the CTL
ImmunoTherapies
Corp. 2000 Stock
Option and Stock
Plan
105,981 shares (8)
$13.03(9)
$1,380,932(9)
$175
Common Stock, par value $.01 per
share, issuable
under the 2004
Employee Stock
Purchase Plan
2,000,000 shares (10)
$14.00(11)
$28,000,000(11)
$3,548
Common Stock, par value $.01 per
share, issuable
under the 2004
Equity Incentive
Plan
5,000,000 shares (12)
$8.64-$14.00 (13)
$62,847,691(13)
$7,963
Common Stock, par value $.01 per
share, issuable
under the 2004
Non-Employee
Directors' Stock
Option Plan
800,000 shares (14)
$14.00(11)
$11,200,000(11)
$1,419
Common Stock, par value $.01 per
shares, issuable
pursuant to options
granted outside of
the Registrant's
plans
240,972 shares (15)
$25.23(16)
$6,079,724(16)
$770
Total
8,592,848 shares
N/A
$113,031,509
$14,322
(1)
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the
"Securities Act"), this Registration Statement also registers any
additional shares of Registrant's Common Stock, par value $0.01 per share
(the "Common Stock"), that become issuable under any of the plans by
reason of any stock dividend, stock split, recapitalization or other
similar transaction effected without receipt of consideration that
increases the number of outstanding shares of Common Stock.
(2)
Comprised solely of shares of Common Stock reserved for issuance upon the
exercise of options outstanding under the Pharmaceutical Discovery
Corporation 1991 Stock Option Plan (the "1991 Plan"). No additional
options may be granted under the 1991 Plan.
(3)
Estimated solely for the purposes of calculating the registration fee
pursuant to Rule 457(h) of the Securities Act. The Proposed maximum
offering price per share and Proposed maximum aggregate offering price for
the 126,099 shares reserved for issuance under the 1991 Plan are
calculated using a weighted average exercise price for such shares of
$6.11.
(4)
Comprised solely of shares of Common Stock reserved for issuance upon the
exercise of options outstanding under the Pharmaceutical Discovery
Corporation 1999 Stock Plan (the "1999 Plan"). No additional options may
be granted under the 1999 Plan.
(5)
Estimated solely for the purposes of calculating the registration fee
pursuant to Rule 457(h) of the Securities Act. The Proposed maximum
offering price per share and Proposed maximum aggregate offering price for
the 305,430 shares reserved for issuance under the 1999 Plan are
calculated using a weighted average exercise price for such shares of
$7.95.
(6)
Comprised solely of shares of Common Stock reserved for issuance upon the
exercise of options outstanding under the AlleCure Corp. 2000 Stock Option
and Stock Plan (the "AlleCure Plan"). No additional options may be
granted under the AlleCure Plan.
(7)
Estimated solely for the purposes of calculating the registration fee
pursuant to Rule 457(h) of the Securities Act. The Proposed maximum
offering price per share and Proposed maximum aggregate offering price for
the 14,366 shares reserved for issuance under the AlleCure Plan are
calculated using a weighted average exercise price for such shares of
$22.59.
(8)
Comprised solely of shares of Common Stock reserved for issuance upon the
exercise of options outstanding under the CTL ImmunoTherapies Corp. 2000
Stock Option and Stock Plan (the "CTL Plan"). No additional
options may be granted under the CTL Plan.
(9)
Estimated solely for the purposes of calculating the registration fee
pursuant to Rule 457(h) of the Securities Act. The Proposed maximum
offering price per share and Proposed maximum aggregate offering price for
the 105,981 shares reserved for issuance under the CTL Plan are calculated
using a weighted average exercise price for such shares of $13.03.
(10)
Represents 2,000,000 shares of Common Stock initially available for
future grants under the Registrant's 2004 Employee Stock Purchase Plan
(the "ESPP"). The ESPP provides that an additional number of shares will
automatically be added annually to the shares authorized for issuance
under the ESPP on the first day of each calendar year, from 2005 until
2014. The number of shares added each year will be equal to the lesser
of: one percent of the total number of shares of Common Stock outstanding
on January 1 of the current fiscal year; 700,000 shares of Common Stock;
or a number of shares of Common Stock that may be determined each year by
the board of directors of MannKind Corporation (the "Registrant").
(11)
This estimate is made pursuant to Rule 457(h) of the Securities Act
solely for purposes of calculating the registration fee, and is based on
the price per share in the initial public offering (the "Offering") of the
Common Stock as set forth in the Registrant's prospectus filed with the
Securities and Exchange Commission (the "Commission") on July 27, 2004
pursuant to Rule 424(b) under the Securities Act.
(12)
Represents 1,334,386 shares of Common Stock reserved for issuance upon
exercise of options outstanding under the Registrant's 2004 Equity
Incentive Plan (the "2004 Plan") and 3,665,614 shares of Common Stock
available for future grants under the 2004 Plan.
(13)
Estimated solely for purposes of calculating the registration fee
pursuant to Rule 457(h) of the Securities Act. The Proposed maximum
offering price per share and Proposed maximum aggregate offering price for
the 1,334,386 shares of Common Stock reserved for issuance upon the
exercise of options outstanding under the 2004 Plan are calculated using a
weighted average exercise price for such shares of $8.64 per share. The
Proposed maximum offering price per share and Proposed maximum aggregate
offering price for the 3,665,614 shares of Common Stock available for
future grants under the 2004 Plan are calculated using the price per share
in the Offering.
(14)
Represents 800,000 shares of Common Stock initially available for future
grants under the Registrant's 2004 Non-Employee Directors' Stock Option
Plan.
(15)
Comprised solely of shares of Common Stock reserved for issuance upon
exercise of outstanding options granted outside of the Registrant's plans.
(16)
Estimated solely for the purposes of calculating the registration fee
pursuant to Rule 457(h) of the Securities Act. The Proposed maximum
offering price per share and Proposed maximum aggregate offering price for
the 240,972 shares reserved for issuance pursuant to outstanding options
granted outside of the Registrant's plans are calculated using a weighted
average exercise price for such shares of $25.23.
TABLE OF CONTENTS
PART I
ITEM 1. PLAN INFORMATION.
ITEM 2. REGISTRANT INFORMATION AND EMPLOYEE PLAN ANNUAL INFORMATION.
PART II
ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.
ITEM 4. DESCRIPTION OF SECURITIES.
ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL.
ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED.
ITEM 8. EXHIBITS.
ITEM 9. UNDERTAKINGS.
SIGNATURES
EXHIBIT INDEX
Opinion of Cooley Godward LLP
Consent of Deloitte & Touche LLP
Table of Contents
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
ITEM 1. PLAN INFORMATION.
Not required to be filed with this Registration Statement.
ITEM 2. REGISTRANT INFORMATION AND EMPLOYEE PLAN ANNUAL INFORMATION.
Not required to be filed with this Registration Statement.
Table of Contents
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.
The Registrant hereby incorporates by reference into this Registration
Statement the following documents previously filed by the Registrant with the
Commission:
(a) The Registrant's prospectus filed on July 28, 2004 pursuant to Rule
424(b) under the Securities Act, relating to the registration statement on Form
S-1 (File No. 333-115020), which contains audited financial statements for the
Registrant's latest fiscal year for which such statements have been filed.
(b) The description of the Common Stock contained in the Registrant's
registration statement on Form 8-A filed on July 23, 2004 (File No. 000-50865),
under the Securities Exchange Act of 1934, as amended (the "Exchange Act"),
including any amendment or report filed for the purpose of updating such
description.
All documents, reports and definitive proxy or information statements
filed pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after
the date of this Registration Statement and prior to the filing of a
post-effective amendment which indicates that all securities offered hereby
have been sold or which deregisters all securities then remaining unsold shall
be deemed to be incorporated by reference into this Registration Statement and
to be a part hereof from the date of filing of such documents. Any statement
contained in a document incorporated or deemed to be incorporated herein by
reference shall be deemed to be modified or superseded for purposes of this
Registration Statement to the extent that a statement herein or in any other
subsequently filed document which also is or is deemed to be incorporated by
reference herein modifies or supersedes that statement. Any such statement so
modified or superseded shall not constitute a part of this Registration
Statement, except as so modified or superseded.
ITEM 4. DESCRIPTION OF SECURITIES.
Not applicable.
ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL.
The validity of the issuance of the common stock offered by this
prospectus and certain other legal matters are being passed on for us by our
counsel, Cooley Godward LLP, San Diego, California.
ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
The Registrant is incorporated under the laws of the State of Delaware.
Section 145 of the Delaware General Corporation Law provides that a Delaware
corporation may indemnify any persons who are, or are threatened to be made,
parties to any threatened, pending or completed action, suit or proceeding,
whether civil, criminal, administrative or investigative (other than an action
by or in the right of such corporation), by reason of the fact that such person
is or was an officer, director, employee or agent of such corporation, or is or
was serving at the request of such corporation as an officer, director,
employee or agent of another corporation or enterprise. The indemnity may
include expenses (including attorneys' fees), judgments, fines and amounts paid
in settlement actually and reasonably incurred by such person in connection
with such action, suit or proceeding, provided that such person acted in good
faith and in a manner he or she reasonably believed to be in or not opposed to
the corporation's best interests and, with respect to any criminal action or
proceeding, had no reasonable cause to believe that his or her conduct was
illegal. A Delaware corporation may indemnify any persons who are, or are
threatened to be made, a party to any threatened, pending or completed action
or suit by or in the right of the corporation by reason of the fact that such
person is or was a director, officer, employee or agent of such corporation, or
is or was serving at the request of such corporation as a director, officer,
employee or agent of another corporation or enterprise. The indemnity may
include expenses (including attorneys' fees) actually and reasonably incurred
by such person in connection with the defense or settlement of such action or
suit provided such person acted in good faith and in a manner he or she
reasonably believed to be in or not opposed to the corporation's best interests
except that no
Table of Contents
indemnification is permitted without judicial approval if the officer or
director is adjudged to be liable to the corporation. Where an officer or
director is successful on the merits or otherwise in the defense of any action
referred to above, the corporation must indemnify him or her against the
expenses which such officer or director has actually and reasonably incurred.
The Registrant's amended and restated certificate of incorporation and amended
and restated bylaws, which will become effective upon the completion of the
Offering, provide for the indemnification of the Registrant's directors and
officers to the fullest extent permitted under the Delaware General Corporation
Law.
Section 102 of the Delaware General Corporation Law permits a corporation
to provide in its certificate of incorporation that a director of the
corporation shall not be personally liable to the corporation or its
stockholders for monetary damages for breach of fiduciary duties as a director,
except for liability:
•
for any transaction from which the director derives an
improper personal benefit;
•
for acts or omissions not in good faith or that involve
intentional misconduct or a knowing violation of law;
•
for acts related to unlawful stock repurchases, redemptions
or other distributions or payment of dividends; or
•
for any breach of a director's duty of loyalty to the
corporation or its stockholders.
The Registrant's amended and restated certificate of incorporation and
amended and restated bylaws include such a provision. Expenses incurred by any
officer or director in defending any such action, suit or proceeding in advance
of its final disposition shall be paid by the Registrant upon delivery to the
Registrant of an undertaking, by or on behalf of such director or officer, to
repay all amounts so advanced if it shall ultimately be determined that such
director or officer is not entitled to be indemnified by the Registrant.
Section 174 of the Delaware General Corporation Law provides, among other
things, that a director, who willfully or negligently approves of an unlawful
payment of dividends or an unlawful stock purchase or redemption, may be held
liable for such actions. A director who was either absent when the unlawful
actions were approved, or dissented at the time, may avoid liability by causing
his or her dissent to such actions to be entered in the books containing
minutes of the meetings of the board of directors at the time such action
occurred or immediately after such absent director receives notice of the
unlawful acts.
As permitted by the Delaware General Corporation Law, the Registrant has
entered into indemnity agreements with each of our directors and executive
officers, that require the Registrant to indemnify such persons against any and
all expenses (including attorneys' fees), witness fees, damages, judgments,
settlements and other amounts incurred (including expenses of a derivative
action) in connection with any action, suit or proceeding, whether actual or
threatened, to which any such person may be made a party by reason of the fact
that such person is or was a director, an officer or an employee of the
Registrant or any of its affiliated enterprises, provided that such person
acted in good faith and in a manner such person reasonably believed to be in or
not opposed to the Registrant's best interests and, with respect to any
criminal proceeding, had no reasonable cause to believe his or her conduct was
unlawful. The indemnification agreements also set forth certain procedures
that will apply in the event of a claim for indemnification thereunder.
At present, there is no pending litigation or proceeding involving any of
the Registrant's directors or executive officers as to which indemnification is
required or permitted, and the Registrant is not aware of any threatened
litigation or proceeding that may result in a claim for indemnification. The
Registrant has an insurance policy covering its officers and directors with
respect to certain liabilities, including liabilities arising under the
Securities Act or otherwise.
ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED.
Not applicable.
Table of Contents
ITEM 8. EXHIBITS.
Exhibit
Number
Description
3.1(1)
Form of Registrant's Amended and Restated Certificate of Incorporation, to be effective upon
completion of the Offering.
3.2(1)
Form of Registrant's Amended and Restated Bylaws, to be effective upon completion of the
Offering.
4.1(1)
Form of Common Stock Certificate.
4.2(1)
Registration Rights Agreement made and entered into as of October 15, 1998 by and among CTL
ImmunoTherapies Corp., Medical Research Group, LLC, McLean Watson Advisory Inc. and Alfred E.
Mann, as amended.
5.1
Opinion of Cooley Godward LLP.
23.1
Consent of Deloitte & Touche
LLP, Independent Registered Public Accounting Firm.
23.2
Consent of Cooley Godward LLP. Reference is made to Exhibit 5.1.
24.1
Power of Attorney. Reference is made to the signature page hereto.
99.1(1)
Pharmaceutical Discovery Corporation 1991 Stock Option Plan.
99.2(1)
Pharmaceutical Discovery Corporation 1999 Stock Plan and Form of Stock Option Plan thereunder.
99.3(1)
AlleCure Corp. 2000 Stock Option and Stock Plan.
99.4(1)
CTL ImmunoTherapies Corp. 2000 Stock Option and Stock Plan.
99.5(1)
2004 Employee Stock Purchase Plan and Form of Offering Document thereunder.
99.6(1)
2004 Equity Incentive Plan and Form of Stock Option Agreement thereunder.
99.7(1)
2004 Non-Employee Directors' Stock Option Plan and Form of Stock Option Agreement thereunder.
(1)
Filed as an exhibit to the Registrant's Registration Statement on Form
S-1, as amended (File No. 333-115020), originally filed with the
Commission on April 30, 2004, and incorporated herein by reference.
ITEM 9. UNDERTAKINGS.
A. The undersigned Registrant hereby undertakes: (1) to file, during any
period in which offers or sales are being made, a post-effective amendment to
this Registration Statement: (i) to include any prospectus required by section
10(a)(3) of the Securities Act; (ii) to reflect in the prospectus any facts or
events arising after the effective date of the registration statement (or the
most recent post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set forth in the
registration statement; and (iii) to include any material information with
respect to the plan of distribution not previously disclosed in the
registration statement or any material change to such information in the
registration statement; (2) that, for the purpose of determining any liability
under the Securities Act, each such post-effective amendment shall be deemed to
be a new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof; and (3) to remove from registration by means of a
post-effective amendment any of the securities being registered which remain
unsold at the termination of the offering.
Table of Contents
B. The undersigned Registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act, each filing of the
Registrant's annual report pursuant to Section 13(a) or 15(d) of the Exchange
Act that is incorporated by reference in this Registration Statement shall be
deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
C. Insofar as indemnification for liabilities arising under the Securities Act
may be permitted to directors, officers and controlling persons of the
Registrant pursuant to the indemnification provisions summarized in Item 6 or
otherwise, the Registrant has been advised that in the opinion of the
Commission such indemnification is against public policy as expressed in the
Securities Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the
Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the Registrant will, unless in
the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue.
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-8 and has duly caused this Registration
Statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Valencia, State of California, on
July 30, 2004.
MANNKIND CORPORATION
By:
/s/ ALFRED E. MANN
Alfred E. Mann
Chief Executive Officer and
Chairman
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS
, that each person whose signature
appears below constitutes and appoints Hakan S. Edstrom, Richard L. Anderson
and David Thomson, and each or any one of them, his or her true and lawful
attorney-in-fact and agent, with full power of substitution and resubstitution,
for him or her and in his or her name, place and stead, in any and all
capacities, to sign any and all amendments (including post-effective
amendments) to this Registration Statement, and to file the same, with all
exhibits thereto, and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorneys-in-fact and
agents, and each of them, full power and authority to do and perform each and
every act and thing requisite and necessary to be done in connection therewith,
as fully to all intents and purposes as he or she might or could do in person,
hereby ratifying and confirming all that said attorneys-in-fact and agents, or
any of them, or their or his substitutes or substitute, may lawfully do or
cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement has been signed by the following persons in the
capacities and on the dates indicated.
Signature
Title
Date
/s/
ALFRED E. MANN
Alfred E. Mann
Chief Executive Officer and
Chairman of the Board of
Directors (
Principal Executive
Officer
)
July 30, 2004
/s/
HAKAN S. EDSTROM
Hakan S. Edstrom
President, Chief Operating
Officer and Director
July 30, 2004
/s/
RICHARD L. ANDERSON
Richard L. Anderson
Corporate Vice President and
Chief Financial Officer
(
Principal Financial and
Accounting Officer
)
July 30, 2004
/s/
KATHLEEN CONNELL, Ph.D.
Kathleen Connell, Ph.D.
Director
July 22, 2004
/s/ RONALD CONSIGLIO
Director
July 30, 2004
Ronald Consiglio
Table of Contents
Signature
Title
Date
/s/
LLEW KELTNER, M.D., Ph.D.
Llew Keltner, M.D., Ph.D.
Director
July 28, 2004
/s/
MICHAEL FRIEDMAN, M.D.
Michael Friedman, M.D.
Director
July 20, 2004
/s/
KENT KRESA
Kent Kresa
Director
July 30, 2004
/s/
DAVID MACCALLUM
David MacCallum
Director
July 22, 2004
Table of Contents
EXHIBIT INDEX
Exhibit
Number
Description
3.1(1)
Form of Registrant's Amended and Restated Certificate of Incorporation, to be effective upon
completion of the Offering.
3.2(1)
Form of Registrant's Amended and Restated Bylaws, to be effective upon completion of the
Offering.
4.1(1)
Form of Common Stock Certificate.
4.2(1)
Registration Rights Agreement made and entered into as of October 15, 1998 by and among CTL
ImmunoTherapies Corp., Medical Research Group, LLC, McLean Watson Advisory Inc. and Alfred E.
Mann, as amended.
5.1
Opinion of Cooley Godward LLP.
23.1
Consent of Deloitte & Touche
LLP, Independent Registered Public Accounting Firm.
23.2
Consent of Cooley Godward LLP. Reference is made to Exhibit 5.1.
24.1
Power of Attorney. Reference is made to the signature page hereto.
99.1(1)
Pharmaceutical Discovery Corporation 1991 Stock Option Plan.
99.2(1)
Pharmaceutical Discovery Corporation 1999 Stock Plan and Form of Stock Option Plan thereunder.
99.3(1)
AlleCure Corp. 2000 Stock Option and Stock Plan.
99.4(1)
CTL ImmunoTherapies Corp. 2000 Stock Option and Stock Plan.
99.5(1)
2004 Employee Stock Purchase Plan and Form of Offering Document thereunder.
99.6(1)
2004 Equity Incentive Plan and Form of Stock Option Agreement thereunder.
99.7(1)
2004 Non-Employee Directors' Stock Option Plan and Form of Stock Option Agreement thereunder.
(1)
Filed as an exhibit to the Registrant's Registration Statement on Form
S-1, as amended (File No. 333-115020), originally filed with the
Commission on April 30, 2004, and incorporated herein by reference.